sodium glycerophosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1318	55073-41-1

Description:

Molecule

Description

Synonyms:

sodium glycerophosphate pentahydrate
sodium glycerophosphate anhydrous
glycophos
sodium glycerophosphate

Molecular weight: 216.04
Formula: C3H7Na2O6P
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 112.88
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 25, 2014	FDA	FRESENIUS KABI USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal growth restriction	79.93	57.63	15	218	7538	63481251

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pantoea agglomerans infection	50.80	42.01	6	360	96	79743926

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B05XA14	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Electrolyte solutions

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypophosphatemia	indication	4996001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
RCS9EQ01V4	UNII
D10489	KEGG_DRUG
1334-74-3	SECONDARY_CAS_RN
4020405	VANDF
C0377349	UMLSCUI
CHEMBL3039567	ChEMBL_ID
CHEMBL3040581	ChEMBL_ID
754	PUBCHEM_CID
DB09561	DRUGBANK_ID
C029620	MESH_SUPPLEMENTAL_RECORD_UI
1423802	RXNORM
15422	MMSL
88596	MMSL
NOCODE	MMSL
d05886	MMSL
005907	NDDF
415542004	SNOMEDCT_US
415543009	SNOMEDCT_US
733766009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Glycophos	Human Prescription Drug Label	1	63323-241	INJECTION, SOLUTION	216 mg	INTRAVENOUS	Unapproved drug for use in drug shortage	3 sections
Glycophos	Human Prescription Drug Label	1	63323-241	INJECTION, SOLUTION	216 mg	INTRAVENOUS	Unapproved drug for use in drug shortage	3 sections
Kabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-712	INJECTION, EMULSION	147 mg	INTRAVENOUS	NDA	28 sections
Kabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-712	INJECTION, EMULSION	147 mg	INTRAVENOUS	NDA	28 sections
Kabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-712	INJECTION, EMULSION	147 mg	INTRAVENOUS	NDA	28 sections
Kabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-712	INJECTION, EMULSION	147 mg	INTRAVENOUS	NDA	28 sections
Kabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-712	INJECTION, EMULSION	147 mg	INTRAVENOUS	NDA	28 sections
Kabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-712	INJECTION, EMULSION	147 mg	INTRAVENOUS	NDA	28 sections
Perikabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-714	INJECTION, EMULSION	105 mg	INTRAVENOUS	NDA	28 sections
Perikabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-714	INJECTION, EMULSION	105 mg	INTRAVENOUS	NDA	28 sections
Perikabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-714	INJECTION, EMULSION	105 mg	INTRAVENOUS	NDA	28 sections
Perikabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-714	INJECTION, EMULSION	105 mg	INTRAVENOUS	NDA	28 sections
Perikabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-714	INJECTION, EMULSION	105 mg	INTRAVENOUS	NDA	28 sections
Perikabiven	HUMAN PRESCRIPTION DRUG LABEL	24	63323-714	INJECTION, EMULSION	105 mg	INTRAVENOUS	NDA	28 sections